| Overall mortality |  | Treatment discontinuation |  |
---|---|---|---|---|
Variable | Adjusted HR (95Â % CI) | P value | Adjusted HR (95Â % CI) | P value |
RCRC (vs. LCRC) | 1.45 (1.18, 1.78) | .0003 | 1.32 (1.08, 1.61) | .0072 |
Female (vs. male) | 1.04(0.90, 1.21) | .5869 | 1.01 (0.87, 1.16) | .9413 |
Age (vs. < 50 y) | Â | .2962 | Â | .0783 |
50-64 | 0.86 (0.70, 1.06) | Â | 0.80 (0.66, 0.98) | Â |
65+ | 0.94 (0.76, 1.17) | Â | 0.82 (0.67, 1.01) | Â |
Stage IV at diagnosis (vs. I-III)a | 1.11 (0.95, 1.28) | .1887 | 1.08 (0.94, 1.25) | .2916 |
Histology (vs. others) | Â | .1096 | Â | .1524 |
Mucinous adenocarcinoma | 1.55 (0.91, 2.65) | Â | 1.69 (0.99, 2.89) | Â |
Non-mucinous adenocarcinoma | 1.04 (0.69, 1.59) | Â | 1.42 (0.93, 2.18) | Â |
Grade (vs. I) | Â | .0009 | Â | .0023 |
 II | 1.24 (0.88, 1.76) |  | 1.02 (0.74, 1.40) |  |
 III | 1.82 (1.21, 2.74) |  | 1.39 (0.95, 2.05) |  |
Undifferentiated or unknown | 1.75 (1.15, 2.65) | Â | 1.50 (1.01, 2.22) | Â |